ArticleCell biochemistry and function2025
Phosphorylation State of RB Modulates Ferroptotic Sensitivity.
Article in Cell biochemistry and function, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecular mechanisms and recent advances in cellular senescence.Cell & bioscience · 2026Review
- Regulation of ferroptosis by transcription factor E2F1.Biochimie · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Tumor suppressor RB is a central regulator of cell cycle progression. By binding to E2F transcription factors, RB can inhibit transcription of E2F target genes to cause cell cycle arrest. Cyclin dependent kinases (CDK) regulate the interaction of RB/E2F by phosphorylating RB at multiple sites. Previously, we observed that CDK2, RB and E2F inhibit ferroptosis. Ferroptosis is a non-apoptotic, iron-dependent form of cell death characterized by toxic lipid peroxidation. Here, we investigate whether RB is a downstream target of CDK activity in the regulation of ferroptosis. We approach this question by overexpressing wild-type (WT) RB or a mutant RB that cannot be phosphorylated by CDKs (RBΔCDK) followed by analysis of ferroptosis. Overexpressing WT-RB reduced sensitivity to ferroptosis while the RBΔCDK mutant increased sensitivity. As we previously found, increasing CDK2 expression reduced ferroptotic sensitivity. This reduction persisted in cells expressing RBΔCDK. However, WT-RB blocked the ability of CDK2 to inhibit ferroptosis. These observations suggest that at least part of the mechanism by which CDK2 inhibits ferroptosis is by phosphorylating RB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.